Brigham and Women’s epidemiologist Ameet Sarpatwari; Jonathan Darrow, a lawyer with the Brigham’s division of pharmacoepidemiology and pharmacoeconomics; and Ariel Stern, an assistant professor at Harvard Business School focusing on health care management, each gave a short presentation on their area of research related to prescription drug costs. The three then sat on a panel moderated by Harvard-MIT Regulatory Science Fellow Michael Sinha, and took audience questions about the FDA, drug costs, and possible options for regulation.
Read more: Tackling high Rx prices